188 related articles for article (PubMed ID: 8961163)
1. Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
Calvo P; Alonso MJ; Vila-Jato JL; Robinson JR
J Pharm Pharmacol; 1996 Nov; 48(11):1147-52. PubMed ID: 8961163
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers.
Calvo P; Vila-Jato JL; Alonso MJ
J Pharm Sci; 1996 May; 85(5):530-6. PubMed ID: 8742946
[TBL] [Abstract][Full Text] [Related]
3. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.
De Campos AM; Sánchez A; Gref R; Calvo P; Alonso MJ
Eur J Pharm Sci; 2003 Sep; 20(1):73-81. PubMed ID: 13678795
[TBL] [Abstract][Full Text] [Related]
4. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid.
Yamaguchi M; Ueda K; Isowaki A; Ohtori A; Takeuchi H; Ohguro N; Tojo K
Biol Pharm Bull; 2009 Jul; 32(7):1266-71. PubMed ID: 19571396
[TBL] [Abstract][Full Text] [Related]
5. Chitosan based nanocarriers for indomethacin ocular delivery.
Badawi AA; El-Laithy HM; El Qidra RK; El Mofty H; El dally M
Arch Pharm Res; 2008 Aug; 31(8):1040-9. PubMed ID: 18787795
[TBL] [Abstract][Full Text] [Related]
6. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution.
Chetoni P; Panichi L; Burgalassi S; Benelli U; Saettone MF
J Ocul Pharmacol Ther; 2000 Aug; 16(4):363-72. PubMed ID: 10977132
[TBL] [Abstract][Full Text] [Related]
8. [Ocular Drug Delivery System-based on Solid Nanoparticles].
Nagai N
Yakugaku Zasshi; 2021; 141(1):47-53. PubMed ID: 33390447
[TBL] [Abstract][Full Text] [Related]
9. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
Liu R; Liu Z; Zhang C; Zhang B
J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
[TBL] [Abstract][Full Text] [Related]
10. [Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil].
Shen JQ; Gan Y; Gan L; Zhu CL; Zhu JB
Yao Xue Xue Bao; 2010 Jan; 45(1):120-5. PubMed ID: 21351461
[TBL] [Abstract][Full Text] [Related]
11. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution.
Klang S; Abdulrazik M; Benita S
Pharm Dev Technol; 2000; 5(4):521-32. PubMed ID: 11109251
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of single-unit commercial immediate-and sustained-release capsules compared with multiple-unit polystyrene microparticles dosage forms of indomethacin.
Tamilvanan S; Sa B
PDA J Pharm Sci Technol; 2008; 62(3):177-90. PubMed ID: 18661867
[TBL] [Abstract][Full Text] [Related]
13. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.
Madhu C; Rix PJ; Shackleton MJ; Nguyen TG; Tang-Liu DD
J Pharm Sci; 1996 Apr; 85(4):415-8. PubMed ID: 8901080
[TBL] [Abstract][Full Text] [Related]
14. Ocular bioavailability of ciprofloxacin in sustained release formulations.
Ke TL; Cagle G; Schlech B; Lorenzetti OJ; Mattern J
J Ocul Pharmacol Ther; 2001 Dec; 17(6):555-63. PubMed ID: 11777179
[TBL] [Abstract][Full Text] [Related]
15. [Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics].
Sun KX; Wang AP; Huang LJ; Liang RC; Liu K
Yao Xue Xue Bao; 2006 Nov; 41(11):1094-8. PubMed ID: 17262954
[TBL] [Abstract][Full Text] [Related]
16. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
[TBL] [Abstract][Full Text] [Related]
17. Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles.
Nagai N; Ogata F; Otake H; Nakazawa Y; Kawasaki N
Int J Nanomedicine; 2019; 14():1213-1227. PubMed ID: 30863055
[TBL] [Abstract][Full Text] [Related]
18. Formulation of indomethacin eye drops via complexation with cyclodextrins.
Halim Mohamed MA; Mahmoud AA
Curr Eye Res; 2011 Mar; 36(3):208-16. PubMed ID: 21275515
[TBL] [Abstract][Full Text] [Related]
19. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
Patel N; Nakrani H; Raval M; Sheth N
Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
[TBL] [Abstract][Full Text] [Related]
20. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration.
Miyazaki S; Takahashi A; Kubo W; Bachynsky J; Löebenberg R
J Pharm Pharm Sci; 2003; 6(2):238-45. PubMed ID: 12935436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
